Technical Analysis for DFFN - Diffusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 4.7 -4.08% -0.20
DFFN closed down 4.08 percent on Tuesday, March 19, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Mar 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Up Down
See historical DFFN trend table...

Date Alert Name Type % Chg
Mar 19 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 19 Narrow Range Bar Range Contraction 0.00%
Mar 19 NR7 Range Contraction 0.00%
Mar 19 NR7-2 Range Contraction 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 18 200 DMA Resistance Bearish -4.08%
Mar 18 1,2,3 Pullback Bullish Bullish Swing Setup -4.08%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.08%

Older signals for DFFN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.
Medicine Biotechnology Cancer Oncology Chemotherapy Radiation Cancer Treatments Radiation Therapy Glioblastoma Macular Degeneration Brain Tumor Glioblastoma Multiforme Signal Transduction Acne Vulgaris Mtor Oncology Applications Protein Kinase B
Is DFFN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.1
52 Week Low 1.83
Average Volume 196,728
200-Day Moving Average 4.9979
50-Day Moving Average 3.0832
20-Day Moving Average 4.2235
10-Day Moving Average 5.173
Average True Range 0.9393
ADX 66.65
+DI 43.2129
-DI 6.8952
Chandelier Exit (Long, 3 ATRs ) 8.1821
Chandelier Exit (Short, 3 ATRs ) 5.2379
Upper Bollinger Band 6.4452
Lower Bollinger Band 2.0018
Percent B (%b) 0.61
BandWidth 105.206582
MACD Line 0.6249
MACD Signal Line 0.6271
MACD Histogram -0.0023
Fundamentals Value
Market Cap 65.9 Million
Num Shares 14 Million
EPS -2.61
Price-to-Earnings (P/E) Ratio -1.80
Price-to-Sales 0.00
Price-to-Book 15.05
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.12
Resistance 3 (R3) 5.12 4.97 5.05
Resistance 2 (R2) 4.97 4.87 4.98 5.03
Resistance 1 (R1) 4.84 4.80 4.77 4.84 5.00
Pivot Point 4.69 4.69 4.66 4.70 4.69
Support 1 (S1) 4.56 4.59 4.49 4.56 4.40
Support 2 (S2) 4.41 4.52 4.42 4.37
Support 3 (S3) 4.28 4.41 4.35
Support 4 (S4) 4.28